Showing results (991-1000 of 1,007) with videos related to

Sort By:
Pageof 101
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialG Gebhart, L E Lamberts, Z Wimana, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 27, 2025
Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National SurveyHossam M Ali, Zainab Yusufali Motiwala, Yara Shatnawi, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|October 19, 2017
One Health Economics to confront disease threatsCatherine Machalaba, Kristine M Smith, Lina Awada, et al.
Biomedicines|July 2, 2021
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer PatientsPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Leukemia|April 23, 2026
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemiaCosima Drewes, Cristina López, Nnamdi Okeke, et al.
Cancers|September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Leukemia|October 4, 2024
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter studyYu-Hung Wang, Chao-Hung Wei, Chien-Chin Lin, et al.
The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.
Pageof 101